Protein Classes
Protein Summary
The dystroglycan complex is involved in a number of processes including laminin and basement membrane assembly, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, and epithelial polarization. Alpha-dystroglycan is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin-G domains. Receptor for laminin-2 (LAMA2) and agrin in peripheral nerve Schwann cells. Beta-dystroglycan is a transmembrane protein that plays important roles in connecting the extracellular matrix to the cytoskeleton. Acts as a cell adhesion receptor in both muscle and non-muscle tissues. Receptor for both DMD and UTRN and, through these interactions, scaffolds axin to the cytoskeleton. Also functions in cell adhesion-mediated signaling and implicated in cell polarity. (Microbial infection) Alpha-dystroglycan acts as a receptor for lassa virus and lymphocytic choriomeningitis virus glycoprotein and class ...more
- ENST00000308775
- ENSP00000312435
- ENSG00000173402
- ENST00000515359
- ENSP00000440705
- ENST00000538711
- ENSP00000438421
- ENST00000539901
- ENSP00000439334
- ENST00000541308
- ENSP00000440590
- ENST00000545947
- ENSP00000442600
- A3a
- DAG
- AGRNR
- 156DAG
- MDDGA9
- MDDGC7
- MDDGC9
- LGMDR16
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 1 | ||
transcription factor perturbation | 0.98 | ||
biological process | 0.93 | ||
molecular function | 0.9 | ||
kinase perturbation | 0.88 | ||
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 493.16 (req: < 5)
Gene RIFs: 67 (req: <= 3)
Antibodies: 337 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 493.16 (req: >= 5)
Gene RIFs: 67 (req: > 3)
Antibodies: 337 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 45
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0
Protein Data Bank (4)
1 – 4 of 4
PDB Structure Id | Ligand | Method | Resolution (Ã…) | M.W. (kDa) | Pub Year | Title |
---|
PDB Structure Id | M.W. | Resolution | Pub Year |
---|
Pathways (27)
Reactome (16)
KEGG (5)
PathwayCommons (1)
WikiPathways (5)
Click on a row in the table to change the structure displayed.
Items per page:
1 – 5 of 16
Data Source | Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|---|
Reactome | Axon guidance | ||||
Reactome | Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | ||||
Reactome | Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | ||||
Reactome | Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | ||||
Reactome | Developmental Biology | ||||
Name | Explore in Pharos | Explore in Source | ||
---|---|---|---|---|
Axon guidance | ||||
Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | ||||
Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | ||||
Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | ||||
Developmental Biology | ||||
Gene Ontology Terms (76)
Functions (10)
Components (31)
Processes (35)
Items per page:
10
1 – 10 of 10
GO Term | Evidence | Assigned by | ||
---|---|---|---|---|
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Direct Assay (IDA) | UniProtKB | |||
Inferred from Physical Interaction (IPI) | UniProtKB | |||
Inferred from Mutant Phenotype (IMP) | UniProtKB | |||
Inferred from Sequence or structural Similarity (ISS) | UniProtKB | |||
Inferred from Electronic Annotation (IEA) | InterPro | |||
Inferred from Electronic Annotation (IEA) | Ensembl | |||
Inferred from Electronic Annotation (IEA) | UniProtKB-KW | |||
Protein-Protein Interactions (165)
1 – 10 of 165
LGALS9
Novelty: 0.00463223
p_int: 0.999999289
p_ni: 7.11e-7
Data Source: BioPlex
PCDHGA5
p_int: 0.999756494
p_ni: 0.000243506
Data Source: BioPlex
PCDHGB4
Novelty: 0.62001206
p_int: 0.999233509
p_ni: 0.000766491
Data Source: BioPlex
LGALS8
Novelty: 0.00746585
p_int: 0.99909176
p_ni: 0.00090824
Data Source: BioPlex
GINM1
p_int: 0.998779617
p_ni: 0.001220382
Data Source: BioPlex
CEACAM21
Novelty: 0.98765432
p_int: 0.998312301
p_ni: 0.001686187
p_wrong: 0.000001512
Data Source: BioPlex
TNF
Novelty: 0.00001974
p_int: 0.997018043
p_ni: 0.002981832
p_wrong: 1.25e-7
Score: 0.205
Data Source: BioPlex,STRINGDB
TCTN2
Novelty: 0.19568118
p_int: 0.995277091
p_ni: 0.004716987
p_wrong: 0.000005922
Data Source: BioPlex
PCDHB11
Novelty: 1.5
p_int: 0.990503171
p_ni: 0.009496828
Data Source: BioPlex
TMEM106A
Novelty: 0.49469965
p_int: 0.990205169
p_ni: 0.009794792
p_wrong: 3.9e-8
Data Source: BioPlex
Publication Statistics
PubMed Score 493.16
PubMed score by year
PubTator Score 282.15
PubTator score by year
Amino Acid Sequence
Residue Counts
Sequence
MRMSVGLSLLLPLSGRTFLLLLSVVMAQSHWPSEPSEAVRDWENQLEASMHSVLSDLHEAVPTVVGIPDG
1-70
TAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGLPLDTDKGVHYISVSATRLGA
70-140
NGSHIPQTSSVFSIEVYPEDHSELQSVRTASPDPGEVVSSACAADEPVTVLTVILDADLTKMTPKQRIDL
140-210
LHRMRSFSEVELHNMKLVPVVNNRLFDMSAFMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAP
210-280
AREGAMSAQLGYPVVGWHIANKKPPLPKRVRRQIHATPTPVTAIGPPTTAIQEPPSRIVPTPTSPAIAPP
280-350
TETMAPPVRDPVPGKPTVTIRTRGAIIQTPTLGPIQPTRVSEAGTTVPGQIRPTMTIPGYVEPTAVATPP
350-420
TTTTKKPRVSTPKPATPSTDSTTTTTRRPTKKPRTPRPVPRVTTKVSITRLETASPPTRIRTTTSGVPRG
420-490
GEPNQRPELKNHIDRVDAWVGTYFEVKIPSDTFYDHEDTTTDKLKLTLKLREQQLVGEKSWVQFNSNSQL
490-560
MYGLPDSSHVGKHEYFMHATDKGGLSAVDAFEIHVHRRPQGDRAPARFKAKFVGDPALVLNDIHKKIALV
560-630
KKLAFAFGDRNCSTITLQNITRGSIVVEWTNNTLPLEPCPKEQIAGLSRRIAEDDGKPRPAFSNALEPDF
630-700
KATSITVTGSGSCRHLQFIPVVPPRRVPSEAPPTEVPDRDPEKSSEDDVYLHTVIPAVVVAAILLIAGII
700-770
AMICYRKKRKGKLTLEDQATFIKKGVPIIFADELDDSKPPPSSSMPLILQEEKAPLPPPEYPNQSVPETT
770-840
PLNQDTMGEYTPLRDEDPNAPPYQPPPPFTAPMEGKGSRPKNMTPYRSPPPYVPP
840-895
MRMSVGLSLLLPLSGRTFLLLLSVVMAQSHWPSEPSEAVRDWENQLEASMHSVLSDLHEAVPTVVGIPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGLPLDTDKGVHYISVSATRLGANGSHIPQTSSVFSIEVYPEDHSELQSVRTASPDPGEVVSSACAADEPVTVLTVILDADLTKMTPKQRIDLLHRMRSFSEVELHNMKLVPVVNNRLFDMSAFMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAPAREGAMSAQLGYPVVGWHIANKKPPLPKRVRRQIHATPTPVTAIGPPTTAIQEPPSRIVPTPTSPAIAPPTETMAPPVRDPVPGKPTVTIRTRGAIIQTPTLGPIQPTRVSEAGTTVPGQIRPTMTIPGYVEPTAVATPPTTTTKKPRVSTPKPATPSTDSTTTTTRRPTKKPRTPRPVPRVTTKVSITRLETASPPTRIRTTTSGVPRGGEPNQRPELKNHIDRVDAWVGTYFEVKIPSDTFYDHEDTTTDKLKLTLKLREQQLVGEKSWVQFNSNSQLMYGLPDSSHVGKHEYFMHATDKGGLSAVDAFEIHVHRRPQGDRAPARFKAKFVGDPALVLNDIHKKIALVKKLAFAFGDRNCSTITLQNITRGSIVVEWTNNTLPLEPCPKEQIAGLSRRIAEDDGKPRPAFSNALEPDFKATSITVTGSGSCRHLQFIPVVPPRRVPSEAPPTEVPDRDPEKSSEDDVYLHTVIPAVVVAAILLIAGIIAMICYRKKRKGKLTLEDQATFIKKGVPIIFADELDDSKPPPSSSMPLILQEEKAPLPPPEYPNQSVPETTPLNQDTMGEYTPLRDEDPNAPPYQPPPPFTAPMEGKGSRPKNMTPYRSPPPYVPP
Find similar targets by: